drug · antibody
cemiplimab
Marketedupdated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 25 investigational indications.
indications
investigational
NSCLCMelanoma
targets
Programmed cell death protein 1
all catalysts(17)
approval · 15
Sep 28, 2018
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jan 18, 2019
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 20, 2019
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jun 25, 2020
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 10, 2020
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 22, 2021
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 8, 2022
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 6, 2024
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 5, 2024
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 8, 2025
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 29, 2025
approval
$REGN810.00+0.81%
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
phase 1 completion · 1
Trials studying cemiplimab
- phase3Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- phase2Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
- phase2Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
- phase2Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- phase1Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- phase1A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- phase3A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- phase2A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
News(3)
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 18d ago
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…biopharma_dive · 3mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 3mo ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that